Curaleaf Holdings (OTC) (TSE:CURA)
OTHER OTC:CURA
Want to see TSE:CURA full AI Analyst Report?
Top Page
Curaleaf Holdings
(OTC:CURA)
Select Model
Select Model
Rating:56Neutral
Price Target:
C$5.00
▲(66.11% Upside)
Action:Reiterated
Date:06/05/26
The score reflects improving financial momentum (revenue rebound and positive operating/free cash flow) and a constructive earnings update with better profitability and refinancing progress. These positives are tempered by ongoing structural profitability/leverage constraints, only mixed technicals with high volatility, and limited valuation support due to negative P/E and no dividend yield data.
Positive Factors
Revenue rebound and improving gross margin
A large TTM revenue rebound and rising gross margin indicate the core vertically integrated model is regaining scale and pricing power. Sustained top-line expansion with higher product-level margins supports recurring operating earnings, funding growth and absorbing market fluctuations over coming quarters.
Negative Factors
Meaningful leverage on the balance sheet
High absolute debt relative to equity constrains financial flexibility and increases interest and refinancing risk. With sizable leverage, management has less room for strategic investments or to absorb shocks, making multi-quarter deleveraging or sustained cash flow generation critical to reduce risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound and improving gross margin
A large TTM revenue rebound and rising gross margin indicate the core vertically integrated model is regaining scale and pricing power. Sustained top-line expansion with higher product-level margins supports recurring operating earnings, funding growth and absorbing market fluctuations over coming quarters.
Read all positive factors
Curaleaf Holdings (CURA) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$4.28B
Dividend YieldN/A
Average Volume (3M)262.68K
Price to Earnings (P/E)―
Beta (1Y)2.03
Revenue Growth-2.25%
EPS Growth55.22%
CountryCA
Employees5,519
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.44
Shares Outstanding232,773,860
10 Day Avg. Volume246,983
30 Day Avg. Volume262,683
Financial Highlights & Ratios
PEG Ratio-1.17
Price to Book (P/B)2.51
Price to Sales (P/S)1.47
P/FCF Ratio24.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$18.72Price Target Upside521.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.77
Revenue Forecast (FY)C$1.34B
Curaleaf Holdings Business Overview & Revenue Model
Company Description
Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through Domestic Operations and International Operations segments. The company engages in the cultivation, production, and sale of cannabis products through ret...
How the Company Makes Money
Curaleaf primarily makes money by selling cannabis and cannabis-derived products through two main channels: (1) retail sales through its company-owned dispensaries and (2) wholesale sales to third-party dispensaries and other licensed operators in...
Curaleaf Holdings Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The call presented several meaningful financial and strategic positives: revenue growth, a move to net income, strong international expansion (+35% YoY), improved adjusted EBITDA and gross margin levels, successful refinancing and balance sheet progress, and a major regulatory catalyst with medical rescheduling that could materially improve tax treatment, banking access, and international opportunities. These positives are tempered by margin compression (notably in international markets), a modest YoY decline in adjusted EBITDA, SG&A increases, inventory-driven low free cash flow in the quarter, and ongoing supply-chain and market-specific headwinds in select U.S. states. On balance, the company highlighted clear operational improvements, product initiatives driving transaction growth, and significant regulatory upside that management expects to unlock, outweighing the current operational and margin challenges.Positive Updates
Revenue Growth
Total Q1 2026 revenue of $324 million, up 6% year-over-year and above guidance; company expects Q2 revenue to rise 2%–3% sequentially (~$333M at midpoint).
Negative Updates
Sequential Revenue Decline
Revenue declined 3% sequentially versus Q4 2025, attributed to normal seasonality.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth
Total Q1 2026 revenue of $324 million, up 6% year-over-year and above guidance; company expects Q2 revenue to rise 2%–3% sequentially (~$333M at midpoint).
Read all positive updates
Company Guidance
Curaleaf guided Q2 revenue to rise 2–3% sequentially from Q1’s $324M (midpoint ≈ $333M), reiterated 2026 CapEx of roughly $80M, and said operating cash should build through the year after Q1 operating cash flow of $21M and free cash flow of $4M; Q1 head‑line metrics were $324M revenue (+6% YoY, -3% QoQ), $157M gross profit (49% gross margin, -220 bps YoY), $63M adjusted EBITDA (20% margin, -4% YoY and -200 bps YoY, including a 170‑bp international drag), net income from continuing operations $70M or $0.09/share (vs. a $50M loss a year ago), cash $106M, inventory up $16M (7% q/q), outstanding debt $565M (acquisition‑related debt reduced by $9M) and a refinanced $475M note with an oversubscribed $500M three‑year facility; management also expects international growth ~25–30% in 2026 (Q1 international +35% YoY), domestic wholesale +19% YoY (retail -2% YoY), additional 280E tax benefits to be recognized in future periods, and broader balance‑sheet/financial services improvements as regulatory clarity progresses.Curaleaf Holdings Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
50
Neutral
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.29B | 1.29B | 1.34B | 1.35B | 1.34B | 1.21B |
| Gross Profit | 562.24M | 498.20M | 639.25M | 614.45M | 579.03M | 687.59M |
| EBITDA | 189.94M | 169.76M | 233.14M | 238.76M | 220.97M | 278.98M |
| Net Income | -114.13M | -235.12M | -215.42M | -281.20M | -376.93M | -109.13M |
Balance Sheet | ||||||
| Total Assets | 2.81B | 2.84B | 2.95B | 3.10B | 3.41B | 3.11B |
| Cash, Cash Equivalents and Short-Term Investments | 106.20M | 101.39M | 93.03M | 91.82M | 163.18M | 299.33M |
| Total Debt | 1.04B | 1.04B | 853.82M | 883.55M | 931.91M | 652.40M |
| Total Liabilities | 1.90B | 2.00B | 1.96B | 1.93B | 2.01B | 1.44B |
| Stockholders Equity | 821.69M | 754.97M | 861.21M | 1.05B | 1.28B | 1.55B |
Cash Flow | ||||||
| Free Cash Flow | 54.52M | 75.80M | 64.42M | 5.05M | -91.96M | -205.92M |
| Operating Cash Flow | 118.85M | 140.35M | 162.57M | 75.26M | 46.40M | -33.96M |
| Investing Cash Flow | -69.52M | -71.80M | -93.83M | -78.69M | -228.62M | -163.97M |
| Financing Cash Flow | -66.95M | -74.78M | -54.24M | -67.02M | 50.54M | 424.80M |
Curaleaf Holdings Technical Analysis
Positive
3.01
Price Trends
12.91
Positive
11.35
Positive
11.45
Positive
Market Momentum
0.51
Negative
61.48
Neutral
77.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CURA, the sentiment is Positive. The current price of 3.01 is below the 20-day moving average (MA) of 14.77, below the 50-day MA of 12.91, and below the 200-day MA of 11.45, indicating a bullish trend. The MACD of 0.51 indicates Negative momentum. The RSI at 61.48 is Neutral, neither overbought nor oversold. The STOCH value of 77.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:CURA.
Curaleaf Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | C$2.52B | 15.55 | 6.59% | ― | 4.14% | 146.77% | |
61 Neutral | C$3.16B | -27.76 | -6.88% | ― | -2.05% | 52.34% | |
56 Neutral | C$4.28B | -27.41 | -12.61% | ― | -2.25% | 55.22% | |
53 Neutral | C$651.02M | -1.52 | -52.88% | ― | 0.59% | 64.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$2.17B | -1.60 | -33.23% | ― | -6.05% | 25.65% | |
46 Neutral | C$572.76M | ― | -35.26% | ― | -9.65% | -55.41% |
* Healthcare Sector Average
TSE:CURA
Curaleaf Holdings
16.21
12.55
342.90%
TSE:WEED
Canopy Growth
1.44
-0.76
-34.55%
TSE:GTII
Green Thumb Industries
11.50
4.53
64.99%
TSE:TRUL
Trulieve Cannabis
16.45
11.26
216.96%
TSE:CL
Cresco Labs
1.24
0.51
69.86%
TSE:VRNO
Verano Holdings
6.32
0.00
0.00%
Curaleaf Holdings Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Curaleaf Extends Executive Automatic Share Disposition Plan for Chief Legal Officer
Neutral
Apr 2, 2026
Curaleaf Holdings announced that Chief Legal Officer Peter Clateman has extended an existing automatic securities disposition plan, enabling the orderly exercise of vested stock options expiring in July 2027. The plan provides for the sale of a po...
Business Operations and StrategyFinancial Disclosures
Curaleaf Sets May 5 Date to Release Q1 2026 Results and Host Investor Call
Neutral
Apr 1, 2026
Curaleaf Holdings, Inc., a major international cannabis consumer products company with operations across medical and adult-use markets and a vertically integrated presence in Europe, Canada, and Australasia, continues to expand its portfolio throu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.